Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,613 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MDD Clear all
Enrolling by invitation Phase 2 Interventional

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

NCT07161700
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions
SPT-300
Drug
Lead sponsor
Seaport Therapeutics
Industry
Eligibility
18 Years to 66 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Chino, California • Garden Grove, California • Glendale, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 4:52 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

NCT06830044
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Milsaperidone, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:52 PM EDT
Not yet recruiting Phase 2 Interventional

The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.

NCT07810738
View directory record Official record
Conditions
Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
Interventions
Aripiprazole Augmentation, Bupropion Augmentation
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 4:52 PM EDT
Completed Not applicable Interventional

Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients

NCT03674138
View directory record Official record
Conditions
Depression, Anxiety, Generalized Anxiety Disorder, Depressive Disorder, Major Depressive Disorder, Cancer
Interventions
DNA-guided choice of therapy, Clinical management
Diagnostic Test · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 25, 2026, 4:52 PM EDT
Recruiting Phase 2 Interventional

Psilocybin rTMS for Treatment Resistant Depression

NCT06132178
View directory record Official record
Conditions
Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression
Interventions
Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin, Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment
Drug · Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
22 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 25, 2026, 4:52 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

NCT04041284
View directory record Official record
Conditions
Migraine, Major Depressive Disorder
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
17
States / cities
Little Rock, Arkansas • San Diego, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 25, 2026, 4:52 PM EDT
Withdrawn No phase listed Observational

Using EEG to Predict Depression Treatment Response to rTMS in Patients With Major Depression

NCT04575285
View directory record Official record
Conditions
Major Depression, Repetitive Transcranial Magnetic Stimulation
Interventions
Electroencephalogram (EEG)
Diagnostic Test
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 25, 2026, 4:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Neural Components Underlying the Treatment of Adolescent Depression

NCT01717508
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 25, 2026, 4:52 PM EDT
Recruiting Not applicable Interventional

Transcranial Direct Current Stimulation for Depression

NCT07042217
View directory record Official record
Conditions
Unipolar Depression
Interventions
transcranial direct current stimulation (tDCS) and mindfulness instruction, Sham tDCS and Mindfulness
Device
Lead sponsor
Soterix Medical
Industry
Eligibility
22 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Woodbridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 4:52 PM EDT
Completed Not applicable Interventional

Trial of Surf and Hike Therapy for Major Depressive Disorder

NCT03302611
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Physical Activity-based Interventions
Behavioral
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 25, 2026, 4:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dichotic Listening as a Predictor of Medication Response in Depression

NCT00296725
View directory record Official record
Conditions
Major Depression, Dysthymia, Depressive Disorder Not Otherwise Specified
Interventions
Fluoxetine, Imipramine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 25, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

NCT02473289
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Sirukumab 50 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
21 Years to 64 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 25, 2026, 4:52 PM EDT
Enrolling by invitation Not applicable Interventional

Causal Role of Rostromedial Prefrontal Cortex for Positive Savoring in Depression

NCT07467473
View directory record Official record
Conditions
Left Rostromedial Prefrontal Cortex - Accelerated Intermittent Theta Burst, Left Dorsolateral Prefrontal Cortex - Accelerated Intermittent Theta Burst, Left Primary Somatosensory Cortex - Accelerated Intermittent Theta Burst
Interventions
Accelerated Intermittent Theta Burst Transcranial Magnetic Stimulation
Device
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 25, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder

NCT01447576
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ADT, OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,036 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
32
States / cities
Arcadia, California • San Diego, California • Sherman Oaks, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 25, 2026, 4:52 PM EDT
Recruiting Phase 2 Interventional

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

NCT07226661
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
SPN-821 2400 mg, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 25, 2026, 4:52 PM EDT
Completed Phase 4 Interventional Results available

Dichotic Listening as a Predictor of Medication Response in Depression

NCT00404755
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia
Interventions
escitalopram, bupropion, imipramine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 25, 2026, 4:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exploring Biomarkers for Depression

NCT01424111
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Healthy Control
Drug · Other
Lead sponsor
Wyss Institute at Harvard University
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 25, 2026, 4:52 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression

NCT05933148
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Siemens 7T MRI, Sham Neurofeedback
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 25, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Pharmacological Intervention Project (Fluoxetine)

NCT00027378
View directory record Official record
Conditions
Alcoholism, Depression
Interventions
fluoxetine (Prozac), Placebo plus Treatment As Usual
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years to 20 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 25, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

NCT02013609
View directory record Official record
Conditions
MDD
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Cerritos, California • Costa Mesa, California • Garden Grove, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 25, 2026, 4:52 PM EDT
Completed Not applicable Interventional Results available

Vagal Nerve Stimulation for Treatment Resistant Major Depression

NCT04990687
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
gammaCore™
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 25, 2026, 4:52 PM EDT
Recruiting No phase listed Observational

Transition Care for FEP

NCT07713849
View directory record Official record
Conditions
Schizoaffective Disorders, Bipolar Disorder With Psychotic Features, Schizophrenia Disorders, Major Depressive Disorder With Psychotic Features, Psychosis NOS
Interventions
Transition Care Team
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • Harvey, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 25, 2026, 4:52 PM EDT
Completed Not applicable Interventional Results available

Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

NCT00186498
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
memantine, Placebo Oral Capsule
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 25, 2026, 4:52 PM EDT
Terminated Phase 3 Interventional

Treatment for Chronic Depression

NCT00204152
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
(Condition 1) Behavioral Activation; (Condition 2) Behavioral Activation and Stress Innoculation
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 58 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 25, 2026, 4:52 PM EDT